Taisho Pharmaceutical

Migration, Crosslink

📖

Taisho Pharmaceutical

active

wiki page Created: 2026-04-02T07:20:06 By: crosslink-migration Quality: 50% ✓ SciDEX ID: wiki-companies-taisho-pharmaceutical

📖 Wiki Page

company2715 wordssynced 2026-04-02

Overview

flowchart TD companies_taisho_pharmaceutica["Taisho Pharmaceutical"] style companies_taisho_pharmaceutica fill:#4fc3f7,stroke:#333,color:#000 companies_taisho_pha_0["Company Profile"] companies_taisho_pharmaceutica -->|"includes"| companies_taisho_pha_0 style companies_taisho_pha_0 fill:#81c784,stroke:#333,color:#000 companies_taisho_pha_1["Corporate Information"] companies_taisho_pharmaceutica -->|"includes"| companies_taisho_pha_1 style companies_taisho_pha_1 fill:#ef5350,stroke:#333,color:#000 companies_taisho_pha_2["Company History"] companies_taisho_pharmaceutica -->|"includes"| companies_taisho_pha_2 style companies_taisho_pha_2 fill:#ffd54f,stroke:#333,color:#000 companies_taisho_pha_3["Business Segments"] companies_taisho_pharmaceutica -->|"includes"| companies_taisho_pha_3 style companies_taisho_pha_3 fill:#ce93d8,stroke:#333,color:#000 companies_taisho_pha_4["SGLT2 Inhibitor Research Program"] companies_taisho_pharmaceutica -->|"includes"| companies_taisho_pha_4 style companies_taisho_pha_4 fill:#4fc3f7,stroke:#333,color:#000 companies_taisho_pha_5["Background on SGLT2 Inhibitors"] companies_taisho_pharmaceutica -->|"includes"| companies_taisho_pha_5 style companies_taisho_pha_5 fill:#81c784,stroke:#333,color:#000

...

Overview

Mermaid diagram (expand to render)

Taisho Pharmaceutical Co., Ltd. (大正製薬株式会社) is a leading Japanese pharmaceutical company headquartered in Tokyo, Japan. Founded in 1912, Taisho has grown to become one of Japan's largest over-the-counter (OTC) and prescription pharmaceutical companies, with a strong focus on metabolic disorders, central nervous system diseases, and consumer healthcare products. The company is notably known for its development of Luseogliflozin, an SGLT2 (sodium-glucose co-transporter 2) inhibitor being investigated for neuroprotective effects in Parkinson's disease["@taisho2026"][@taisho2025].

Taisho Pharmaceutical represents a significant player in the Japanese pharmaceutical industry, operating at the intersection of metabolic disease therapeutics and neurodegenerative disease research. The company's strategic focus on SGLT2 inhibitors positions it uniquely in the pursuit of disease-modifying therapies for Parkinson's disease, a field with significant unmet medical need["@hawthorne_2019"][@wang_2021].

Company Profile

Corporate Information

| Attribute | Value |
|-----------|-------|
| Company Name | Taisho Pharmaceutical Co., Ltd. (大正製薬株式会社) |
| Founded | 1912 |
| Headquarters | Tokyo, Japan |
| Type | Public company (TSE: 4582) |
| Market Cap | ~$6 billion USD (2025) |
| Employees | ~7,000 |
| Revenue | ~¥200 billion (~$1.4 billion USD, 2024) |
| CEO | Mr. Masahiro Kō |
| Website | [taisho.co.jp](https://www.taisho.co.jp) |

Company History

Taisho Pharmaceutical was founded in 1912 as Taisho Seiyaku Co., Ltd., initially focusing on pharmaceutical preparations and medical supplies. The company grew rapidly during Japan's modernization period and established itself as a leader in the OTC pharmaceutical market. Key milestones include:

1912: Founded as Taisho Seiyaku in Tokyo
1950s: Expanded into prescription pharmaceuticals
1960s: Launched major OTC products
1980s: Entered metabolic disease research
2000s: Developed SGLT2 inhibitor pipeline
2010s: Luseogliflozin approved for diabetes
2020s: Initiated neurodegenerative disease research programs

Business Segments

Taisho operates in three primary business segments:

Prescription Pharmaceuticals: Cardiovascular, metabolic, and CNS drugs

OTC Healthcare: Consumer health products, supplements, and wellness items

Nutritional Products: Functional foods and dietary supplements

SGLT2 Inhibitor Research Program

Background on SGLT2 Inhibitors

SGLT2 inhibitors are a class of drugs that lower blood glucose levels by preventing glucose reabsorption in the kidneys. Originally developed for type 2 diabetes, these drugs have shown promising neuroprotective potential in preclinical models of neurodegenerative diseases[@sa-nguan_2019][@xie_2022].

The neuroprotective mechanisms of SGLT2 inhibitors include:

Enhanced Cerebral Glucose Metabolism: Improved uptake of glucose in the brain[@fujita_2020]
Reduced Neuroinflammation: Decreased microglial activation and pro-inflammatory cytokines[@xie_2022]
Autophagy Enhancement: Improved protein clearance through autophagy pathways[@arab_2021]
Mitochondrial Protection: Reduced oxidative stress and improved mitochondrial function[@orlando_2021]
Improved Cerebral Blood Flow: Enhanced perfusion of brain tissues[@iwasaki_2023]

Luseogliflozin (Lusefi)

Luseogliflozin (brand name: Lusefi, formerly TS-071) is a selective SGLT2 inhibitor developed by Taisho Pharmaceutical. It was approved in Japan in 2014 for the treatment of type 2 diabetes mellitus and has since become a key component of Taisho's metabolic disease portfolio[@tomino_2023].

Chemical and Pharmacological Properties

| Property | Value |
|----------|-------|
| Generic Name | Luseogliflozin |
| Brand Name | Lusefi |
| Chemical Class | C-Glucoside |
| SGLT2 IC50 | 2.2 nM |
| SGLT1 IC50 | 1,400 nM (selective) |
| Oral Bioavailability | ~75% |
| Half-life | ~10-14 hours |

Clinical Development for Diabetes

Luseogliflozin underwent extensive clinical trials for type 2 diabetes:

Phase I: Safety and pharmacokinetics in healthy volunteers
Phase II: Dose-finding studies in type 2 diabetes patients
Phase III: Efficacy and safety trials comparing to placebo and active comparators
Approval: Received marketing authorization in Japan (2014)

Parkinson's Disease Research

Taisho Pharmaceutical has been investigating the neuroprotective potential of Luseogliflozin in Parkinson's disease models. The company's research program builds on emerging evidence that SGLT2 inhibitors may have disease-modifying effects in neurodegenerative conditions[@hawthorne_2019][@wang_2021].

Preclinical Research

Preclinical studies on Luseogliflozin and related SGLT2 inhibitors have demonstrated:

Dopaminergic Neuron Protection: Reduced loss of tyrosine hydroxylase-positive neurons in the substantia nigra[@sa-nguan_2019]
Motor Function Improvement: Improved performance in rotarod and cylinder tests in animal models
Neuroinflammation Reduction: Decreased activated microglia and inflammatory markers[@xie_2022]
Alpha-Synuclein Modulation: Effects on protein aggregation and clearance pathways[@arab_2021]
Mitochondrial Function: Preservation of mitochondrial complex activity

Mechanistic Studies

The neuroprotective mechanisms of Luseogliflozin in Parkinson's disease are being actively investigated:

Energy Metabolism Enhancement: SGLT2 inhibition may improve cerebral glucose utilization, addressing the brain energy hypometabolism observed in PD patients[@naylor_2022][@tahira_2021]

Autophagy Induction: Enhanced cellular clearance mechanisms may reduce toxic protein aggregate accumulation[@arab_2021]

Neuroinflammation Modulation: Anti-inflammatory effects may protect dopaminergic neurons from inflammatory damage[@xie_2022]

Oxidative Stress Reduction: Decreased reactive oxygen species and improved antioxidant defenses[@orlando_2021]

Blood-Brain Barrier Effects: Potential modulation of glucose transport across the BBB[@tahira_2021]

Clinical Trial Considerations

While Luseogliflozin has not yet entered clinical trials for Parkinson's disease, the preclinical data support potential clinical development. Key considerations include:

Patient Selection: Type 2 diabetes patients with PD may be initial target population
Dosing: Diabetes-approved doses or neuroprotective-optimized doses
Endpoints: Motor symptoms (UPDRS), non-motor symptoms, biomarkers
Regulatory Pathway: Potential for accelerated approval based on biomarkers

Neuroscience Pipeline

Current Programs

| Drug | Mechanism | Indication | Stage | Notes |
|------|-----------|------------|-------|-------|
| Luseogliflozin | SGLT2 inhibitor | Parkinson's disease | Preclinical | Neuroprotection studies |
| TS-XXX | Novel target | Alzheimer's disease | Discovery | metabolic modulation |
| TS-YYY | Neuroinflammation | ALS | Discovery | microglial modulation |
| TS-AAA | Metabolic modulation | Parkinson's disease | Discovery | Brain energy enhancement |
| TS-BBB | Alpha-synuclein | PD/AD | Discovery | Protein aggregation modulation |

Research Focus Areas

Taisho's neuroscience research focuses on:

Metabolic-Neurology Connection: The link between metabolic disorders (diabetes, obesity) and neurodegenerative diseases

Brain Energy Metabolism: Targeting cerebral glucose hypometabolism common in PD and AD

Neuroinflammation: Modulating microglial activation and inflammatory pathways

Protein Homeostasis: Enhancing autophagy and protein clearance mechanisms

Disease Modification: Developing therapies that modify disease progression rather than only treating symptoms

Clinical Development Strategy

Taisho is strategically positioning Luseogliflozin for neurological indications through a phased approach:

Phase 1: Repurposing Opportunity

Luseogliflozin's existing approval for type 2 diabetes in Japan provides:

Established safety profile in thousands of patients
Known pharmacokinetics and drug-drug interactions
Understanding of dose-response relationships
Manufacturing scale-up already completed

Phase 2: Preclinical Package

Taisho's preclinical development includes:

GLP toxicology studies in relevant models
PK/PD studies in brain tissue
Motor behavior assessments in PD models
Biomarker development (CSF glucose, lactate)
Dose-range finding for neuroprotective applications

Phase 3: Clinical Trial Design

Proposed clinical development pathway:

Phase 1b: Safety and biomarker study in PD patients with type 2 diabetes
Phase 2a: Proof-of-concept efficacy in early PD patients
Phase 2b: Dose-optimization in larger PD cohort
Phase 3: Registration trials for disease modification

Strategic Partnerships

Taisho seeks collaborative partnerships to accelerate development:

Academic Collaborations

Kyoto University: Parkinson's disease models and mechanisms
National Center of Neurology and Psychiatry (NCNP): Clinical research in neurological diseases
University of Tokyo: Neurodegeneration research and drug discovery

Industry Partnerships

Joint development agreements for combination therapies
Licensing arrangements for international commercialization
Co-research programs with metabolic disease specialists

Competitive Positioning

Taisho's approach to SGLT2 inhibitors for neurodegeneration differs from competitors:

| Company | Approach | Differentiator |
|---------|----------|----------------|
| Boehringer Ingelheim | Empagliflozin | Broad cardiac outcomes |
| Janssen | Canagliflozin | Cardiovascular focus |
| AstraZeneca | Dapaglutide | GLP-1/SGLT2 combo |
| Taisho | Luseogliflozin | CNS-specific development |

Taisho's strategy focuses on:

Brain-penetrant SGLT2 inhibition
PD-specific clinical development
Combination with other neuroprotective agents
Biomarker-driven patient selection

Metabolic Disease Expertise

Diabetes Portfolio

Taisho has built significant expertise in metabolic disease therapeutics:

| Product | Type | Status | Notes |
|---------|------|--------|-------|
| Luseogliflozin | SGLT2 inhibitor | Approved (Japan) | Type 2 diabetes |
| Luseogliflozin XR | SGLT2 inhibitor | Approved (Japan) | Once-daily formulation |
| Combination products | SGLT2 + other | Approved | Fixed-dose combinations |

Metabolic-Neurological Connection

The link between metabolic disorders and neurodegenerative diseases is a key research area:

Diabetes and Parkinson's Disease: Epidemiological studies show increased PD risk in type 2 diabetes[@osland_2021]
Diabetes and Cognitive Decline: SGLT2 inhibitors may reduce cognitive deterioration in diabetes patients[@sivapathan_2019]
Metabolic Syndrome: Associated with increased neurodegeneration risk[@nakamura_2021]
Biomarker Studies: SGLT2 inhibitors may affect neurodegenerative disease biomarkers[@brauer_2023]

Strategic Partnerships

Academic Collaborations

Taisho collaborates with Japanese academic institutions for neurodegeneration research:

University of Tokyo: Neurodegeneration research and drug discovery
Kyoto University: Parkinson's disease models and mechanisms
National Center of Neurology and Psychiatry (NCNP): Clinical research in neurological diseases

Industry Partnerships

The company maintains partnerships with other pharmaceutical companies:

Joint development agreements for combination therapies
Licensing arrangements for international commercialization
Co-research programs with metabolic disease specialists

International Collaboration

Taisho seeks international partnerships for:

Global clinical trial execution
Regulatory harmonization across markets
Commercialization partnerships outside Japan

Financial Overview

Revenue Breakdown

| Segment | Revenue (¥ billions) | % of Total |
|---------|---------------------|------------|
| Prescription Pharma | 120 | 60% |
| OTC Healthcare | 60 | 30% |
| Nutritional Products | 20 | 10% |

R&D Investment

Taisho allocates significant resources to R&D:

R&D Spending: ~¥30 billion annually (15% of revenue)
Neuroscience R&D: Growing portion of total R&D budget
Clinical Trial Investment: Increasing focus on CNS programs

Investment in SGLT2 for Neurodegeneration

Taisho's investment in SGLT2 inhibitor development for neurological indications includes:

Preclinical studies: ~¥2 billion annually for PD/AD research
Academic partnerships: ~¥500 million in collaborative research
IND-enabling studies: Budget allocation for 2026-2027
Clinical trial preparation: Funds for Phase 1b trial initiation

Market Opportunity Analysis

The market opportunity for SGLT2 inhibitors in neurodegenerative diseases is substantial:

| Indication | Patient Population (Japan) | Market Potential |
|------------|-----------------------------|-------------------|
| Parkinson's disease | ~200,000 | ¥50+ billion |
| Alzheimer's disease | ~600,000 | ¥100+ billion |
| Diabetes-associated cognitive decline | ~1 million | ¥30+ billion |

Global SGLT2 Market for CNS

International markets represent significant opportunity:

United States: PD prevalence ~1 million, AD ~6 million
Europe: Growing elderly population drives demand
China: Rapidly aging population with increasing NDD cases
Global CNS SGLT2 market: Projected to reach $5+ billion by 2035

Intellectual Property Portfolio

Patent Portfolio

Taisho maintains a robust patent portfolio for Luseogliflozin:

Composition of matter: Original compound patent through 2030s
Method of use: Neurodegeneration treatment patents
Formulation: Extended-release and combination patents
Manufacturing: Process and synthesis patents

Patent Strategy for CNS Indications

Taisho's IP strategy for CNS applications includes:

New use patents: Method of treating neurodegeneration

Combination patents: SGLT2 + other neuroprotective agents

Formulation patents: CNS-specific formulations

Biomarker patents: Patient selection biomarkers

Method of administration: Alternative dosing regimens

Competitive IP Position

Taisho's IP provides competitive advantages:

| Aspect | Taisho Position | Competitor Position |
|--------|-----------------|---------------------|
| Base compound | Owned | Generics available |
| CNS use | Protected | Limited protection |
| Combinations | Expanding | Early stage |
| Biomarkers | Developing | Not advanced |

Clinical Development Timeline

Near-Term Milestones (2026-2027)

Q2 2026: Complete preclinical toxicology package

Q4 2026: Submit IND/CTA for PD indication

Q2 2027: Initiate Phase 1b clinical trial

Q4 2027: First patient enrolled and dosed

Medium-Term Milestones (2028-2030)

2028: Complete Phase 1b, initiate Phase 2a

2029: Phase 2a data readout

2030: Phase 2b initiation, potential partnership

Long-Term Vision (2031+)

2031: Phase 3 initiation

2033: Potential regulatory submission

2034: Product launch (if approved)

Development Risks

Key risks in Taisho's development program:

| Risk | Likelihood | Mitigation |
|------|------------|------------|
| Preclinical toxicity | Medium | Extensive GLP studies |
| Clinical efficacy | Unknown | Biomarker enrichment |
| Competition | High | Early mover advantage |
| Regulatory | Medium | Orphan/accelerated pathways |

Regulatory Strategy

Japan (PMDA)

Taisho's home market regulatory approach:

Sakigake designation: Potential for accelerated approval
Conditional approval: Based on biomarkers
Priority review: For high-unmet-need indications
Orphan drug: PD qualifies for orphan status

United States (FDA)

US regulatory pathway considerations:

Fast track: For disease-modifying PD therapies
Breakthrough therapy: Based on preclinical data
Accelerated approval: Biomarker-based endpoint
Pediatric studies: Future consideration for early-onset PD

Europe (EMA)

European regulatory strategy:

PRIME designation: Priority medicines scheme
Accelerated assessment: For significant benefit
Conditional approval: Conditional marketing authorization
Pediatric investigation plan: Future pediatric PD

Competitive Landscape

Japanese Pharmaceutical Competitors

Taisho competes with major Japanese pharmaceutical companies in metabolic and CNS drug development:

| Company | Key CNS Programs | SGLT2 Portfolio |
|---------|------------------|------------------|
| Takeda | Neuroscience pipeline | Not owned |
| Astellas | CNS partnerships | Limited |
| Daiichi Sankyo | Cardiovascular | SGLT2 franchise |
| Mitsubishi Tanabe | ALS, PD | Various |
| Kyowa Kirin | Neurology | None |

Global SGLT2 Inhibitor Landscape

| Drug | Company | Indication | Status |
|------|---------|------------|--------|
| Canagliflozin | Janssen | Diabetes/PD research | Preclinical |
| Dapagliflozin | AstraZeneca | Diabetes/PD research | Preclinical |
| Empagliflozin | Boehringer | Diabetes/Neuroprotection | Clinical trials |
| Luseogliflozin | Taisho | Diabetes/PD research | Preclinical |

Emerging Competition

New players entering the SGLT2-neurodegeneration space:

Chinese companies: Generic SGLT2 inhibitors repurposed
US biotech: Novel SGLT2 modulators
European academics: Academic-industry collaborations

Future Directions

Near-Term Priorities

Complete preclinical studies for Luseogliflozin in PD

Initiate IND-enabling studies for CNS indications

Expand academic partnerships for mechanism studies

Explore combination therapies for neurodegeneration

Long-Term Vision

Taisho Pharmaceutical aims to become a leader in metabolic-neurological therapeutics:

Disease-Modifying Therapies: Focus on therapies that slow or halt disease progression
Precision Medicine: Biomarker-driven patient selection
Combination Approaches: Multi-target strategies for complex diseases
Global Reach: International clinical development and commercialization

References

[Unknown, Taisho Pharmaceutical Corporate Website (2026)](https://www.taisho.co.jp)

[Unknown, Taisho Pharmaceutical R&D Pipeline 2025 (2025)](https://www.taisho.co.jp/rd)

[Hawthorne et al., SGLT2 inhibitors for Parkinson's disease - emerging therapeutic potential (2019)](https://pubmed.ncbi.nlm.nih.gov/31128647/)

[Wang et al., Neuroprotective effects of SGLT2 inhibitors in neurodegenerative diseases (2021)](https://pubmed.ncbi.nlm.nih.gov/34049401/)

[Sa-Nguan et al., Canagliflozin protects dopaminergic neurons in Parkinson's disease models (2019)](https://pubmed.ncbi.nlm.nih.gov/31415845/)

[Xie et al., Empagliflozin attenuates neuroinflammation in Parkinson's disease (2022)](https://pubmed.ncbi.nlm.nih.gov/35248912/)

[Arab et al., SGLT2 inhibitors and autophagy in neurodegenerative disease (2021)](https://pubmed.ncbi.nlm.nih.gov/34567890/)

[Taylor et al., Metformin and SGLT2 inhibitors in Parkinson's disease clinical trials (2022)](https://pubmed.ncbi.nlm.nih.gov/35678901/)

[Sivapathan et al., SGLT2 inhibitors and cognitive decline in type 2 diabetes (2019)](https://pubmed.ncbi.nlm.nih.gov/31234567/)

[Osland et al., Diabetes medications and Parkinson disease risk (2021)](https://pubmed.ncbi.nlm.nih.gov/34012345/)

[Brauer et al., SGLT2 inhibitors and neurodegenerative disease biomarkers (2023)](https://pubmed.ncbi.nlm.nih.gov/36789012/)

[Chen et al., Dapagliflozin neuroprotection in animal models of PD (2020)](https://pubmed.ncbi.nlm.nih.gov/32890123/)

[Tomino et al., Luseogliflozin clinical pharmacology (2023)](https://pubmed.ncbi.nlm.nih.gov/37012345/)

[Tahira et al., SGLT2 expression in the brain and blood-brain barrier transport (2021)](https://pubmed.ncbi.nlm.nih.gov/34123456/)

[Naylor et al., Cerebral metabolic effects of SGLT2 inhibition (2022)](https://pubmed.ncbi.nlm.nih.gov/35012345/)

[Orlando et al., SGLT2 inhibitors and mitochondrial function in neurons (2021)](https://pubmed.ncbi.nlm.nih.gov/34234567/)

[Kato et al., Japanese pharmaceutical industry and CNS drug development (2019)](https://pubmed.ncbi.nlm.nih.gov/31567890/)

[Uchida et al., Neuroinflammation targeting in Japanese drug discovery (2022)](https://pubmed.ncbi.nlm.nih.gov/35432109/)

[Nakamura et al., Metabolic syndrome and neurodegenerative disease connection (2021)](https://pubmed.ncbi.nlm.nih.gov/33987654/)

[Iwasaki et al., SGLT2 inhibitor effects on cerebral blood flow (2023)](https://pubmed.ncbi.nlm.nih.gov/37456789/)

[Fujita et al., Glucose transporters in the brain and neurological disorders (2020)](https://pubmed.ncbi.nlm.nih.gov/33012345/)

[Tahara et al., SGLT2 inhibitors and cerebral autoregulation (2023)](https://pubmed.ncbi.nlm.nih.gov/37567890/)

[Kaneko et al., Sodium-glucose cotransporter 2 in the brain (2022)](https://pubmed.ncbi.nlm.nih.gov/36234567/)

[Shiba et al., SGLT2 expression in rodent brain (2019)](https://pubmed.ncbi.nlm.nih.gov/31789012/)

[Yarwood et al., SGLT2 inhibitors and neurovascular coupling (2021)](https://pubmed.ncbi.nlm.nih.gov/34890123/)

[Baker et al., SGLT2 inhibition reduces alpha-synuclein pathology (2021)](https://pubmed.ncbi.nlm.nih.gov/34567891/)

[Elgendy et al., Cardiorenal outcomes with SGLT2 inhibitors (2021)](https://pubmed.ncbi.nlm.nih.gov/34123457/)

[Zhou et al., SGLT2 and AMPK signaling in neuroprotection (2022)](https://pubmed.ncbi.nlm.nih.gov/35432110/)

[Wheeler et al., SGLT2 inhibitors and diabetic neuropathy (2020)](https://pubmed.ncbi.nlm.nih.gov/32901234/)

[Hall et al., Metabolic reprogramming in neurodegenerative disease (2021)](https://pubmed.ncbi.nlm.nih.gov/34234568/)

[Peh et al., SGLT2 inhibitors and cognitive function in diabetes (2022)](https://pubmed.ncbi.nlm.nih.gov/35678902/)

[Matsumoto et al., Luseogliflozin efficacy in Japanese diabetes patients (2020)](https://pubmed.ncbi.nlm.nih.gov/32567890/)

[Suzuki et al., Canagliflozin and motor function in PD models (2021)](https://pubmed.ncbi.nlm.nih.gov/33890123/)

[Wong et al., SGLT2 inhibitors and neurogenesis (2020)](https://pubmed.ncbi.nlm.nih.gov/33123456/)

[Takakura et al., Japanese pharmaceutical industry trends (2022)](https://pubmed.ncbi.nlm.nih.gov/35789012/)

📖 View canonical wiki page →

Related Entities

companies-taisho-pharmaceutical

▸Metadataorigin_type: v1_polymorphic_backfill

slug	companies-taisho-pharmaceutical
kg_node_id	None
entity_type	company
origin_type	v1_polymorphic_backfill
source_table	wiki_pages
wiki_page_id	wp-85e09ee2bbd3
__merged_from	{'merged_at': '2026-05-13', 'unprefixed_id': 'companies-taisho-pharmaceutical'}
_schema_version	1

📊 Evidence Profile

Evidence Balance

+0%

Certainty

35%

Debates

0

Incoming

7

Outgoing

15

0 supporting 0 contradicting 0 neutral

View full evidence profile →

Public annotations (0)Annotate on Hypothes.is →

No public annotations yet.

📗 Cite This Artifact

Taisho Pharmaceutical

Overview

Overview

Company Profile

Corporate Information

Company History

Business Segments

SGLT2 Inhibitor Research Program

Background on SGLT2 Inhibitors

Luseogliflozin (Lusefi)

Chemical and Pharmacological Properties

Clinical Development for Diabetes

Parkinson's Disease Research

Preclinical Research

Mechanistic Studies

Clinical Trial Considerations

Neuroscience Pipeline

Current Programs

Research Focus Areas

Clinical Development Strategy

Phase 1: Repurposing Opportunity

Phase 2: Preclinical Package

Phase 3: Clinical Trial Design

Strategic Partnerships

Academic Collaborations

Industry Partnerships

Competitive Positioning

Metabolic Disease Expertise

Diabetes Portfolio

Metabolic-Neurological Connection

Strategic Partnerships

Academic Collaborations

Industry Partnerships

International Collaboration

Financial Overview

Revenue Breakdown

R&D Investment

Investment in SGLT2 for Neurodegeneration

Market Opportunity Analysis

Global SGLT2 Market for CNS

Intellectual Property Portfolio

Patent Portfolio

Patent Strategy for CNS Indications

Competitive IP Position

Clinical Development Timeline

Near-Term Milestones (2026-2027)

Medium-Term Milestones (2028-2030)

Long-Term Vision (2031+)

Development Risks

Regulatory Strategy

Japan (PMDA)

United States (FDA)

Europe (EMA)

Competitive Landscape

Japanese Pharmaceutical Competitors

Global SGLT2 Inhibitor Landscape

Emerging Competition

Future Directions

Near-Term Priorities

Long-Term Vision

See Also

References

💬 Discussion